These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 29266809)

  • 1. Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
    Faucette S; Wagh S; Trivedi A; Venkatakrishnan K; Gupta N
    Clin Transl Sci; 2018 Mar; 11(2):123-146. PubMed ID: 29266809
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
    Jørgensen JT; Hersom M
    Clin Pharmacol Ther; 2018 Jun; 103(6):999-1008. PubMed ID: 29197081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Premarket Evidence and Postmarketing Requirements for Real-Time Oncology Review Indication Approvals.
    Mooghali M; Mohammad A; Wallach JD; Mitchell AP; Ross JS; Ramachandran R
    JAMA Netw Open; 2024 May; 7(5):e249233. PubMed ID: 38691363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer drugs remain FDA approved despite lack of benefit, study finds.
    McCarthy M
    BMJ; 2016 Dec; 355():i6568. PubMed ID: 27923801
    [No Abstract]   [Full Text] [Related]  

  • 5. Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology.
    Farha M; Masson E; Tomkinson H; Mugundu G
    J Clin Pharmacol; 2019 Apr; 59(4):463-471. PubMed ID: 30536979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Development of Molecularly Targeted Oncology Drugs.
    Patel SK; Leong R; Zhao H; Barone A; Casey D; Liu Q; Burckart GJ; Reaman G
    Clin Pharmacol Ther; 2018 Aug; 104(2):384-389. PubMed ID: 29226303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory watch: Why do oncology drugs fail to gain US regulatory approval?
    Khozin S; Liu K; Jarow JP; Pazdur R
    Nat Rev Drug Discov; 2015 Jul; 14(7):450-1. PubMed ID: 26000722
    [No Abstract]   [Full Text] [Related]  

  • 8. Factors That Influence FDA Decisions for Postmarketing Requirements and Commitments During Review of Oncology Products.
    Hyogo A; Kaneko M; Narukawa M
    J Oncol Pract; 2018 Jan; 14(1):e34-e41. PubMed ID: 29136389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
    Barone A; Casey D; McKee AE; Reaman G
    Pediatr Blood Cancer; 2019 Aug; 66(8):e27809. PubMed ID: 31144772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncology approvals in 2020: a year of firsts in the midst of a pandemic.
    Amiri-Kordestani L; Pazdur R
    Nat Rev Clin Oncol; 2021 Mar; 18(3):129-130. PubMed ID: 33514911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
    Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
    Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: treatments in urologic oncology.
    Ning YM; Maher VE
    Urol Oncol; 2015 Mar; 33(3):137-42. PubMed ID: 25613202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
    Hierro C; Matos I; Martin-Liberal J; Ochoa de Olza M; Garralda E
    Clin Cancer Res; 2019 Jun; 25(11):3210-3219. PubMed ID: 30670489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. US Food and Drug Administration Support for Oncology Drug Development During COVID-19.
    Kadakia KT; Pazdur R; Shah A
    JAMA Oncol; 2021 Jan; 7(1):27-28. PubMed ID: 33030504
    [No Abstract]   [Full Text] [Related]  

  • 15. Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.
    Brackman DJ; Giacomini KM
    Clin Pharmacol Ther; 2018 Feb; 103(2):233-242. PubMed ID: 29023674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. StatBite. FDA-required postmarketing studies, 1992-2008.
    J Natl Cancer Inst; 2010 Sep; 102(17):1303. PubMed ID: 20739654
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
    Kluetz PG; Keegan P; Demetri GD; Thornton K; Sul J; Kim J; Katzen H; Burke LB; Harvey RD; Alebachew E; Agrawal S; Nair A; Donoghue M; Pierce WF; Shord SS; Gao JJ; Pazdur R
    Clin Cancer Res; 2021 Feb; 27(4):916-921. PubMed ID: 33257426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 19. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
    Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.